Subscribe To
Evelo biosciences provides clinical and business updates
– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate ob...
February 1, 2023, 12:30 pm
Arcutis presents new phase 2 long-term data showing sustained efficacy and clearance for a median of 10 months with roflumilast cream in adults with chronic plaque psoriasis
During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any t...
January 14, 2023, 9:00 am
Roivant sciences: a solid year of progress and good prospects for 2023
Roivant's differentiated approach to the drug development business has been hit and miss. The company's subsidiary Dermavant won a first approval this...
December 20, 2022, 3:32 pm
Can-fite biopharma shares jump after piclidenoson data in psoriasis trial
Can-Fite BioPharma Ltd (NYSE: CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate ...
June 29, 2022, 7:57 am
Arcutis: roflumilast has excellent data and high probability of fda approval
Phase 3 data from the DERMIS Phase 3 trials demonstrated an excellent efficacy profile for roflumilast in psor...
April 5, 2022, 5:01 pm
Can-fite biopharma flags delay in piclidenoson data readout from psoriasis study
Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort ...
March 8, 2022, 8:35 am
Evelo biosciences' psoriasis candidate shows reductions in inflammatory cytokines
Evelo Biosciences Inc EVLO has announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed E...
February 7, 2022, 7:54 am
Evelo biosciences' psoriasis candidate shows reductions in inflammatory cytokines
Evelo Biosciences Inc EVLO has announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed E...
February 7, 2022, 7:54 am
Evelo biosciences' psoriasis candidate shows reductions in inflammatory cytokines
Evelo Biosciences Inc EVLO has announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed E...
February 7, 2022, 7:54 am
Abbvie forecasts 2022 profit above estimates on strong sales of botox, skyrizi
AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer ...
February 2, 2022, 7:46 am
Abbvie forecasts 2022 profit above estimates on strong sales of botox, skyrizi
AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer ...
February 2, 2022, 7:46 am
Abbvie forecasts 2022 profit above estimates on strong sales of botox, skyrizi
AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer ...
February 2, 2022, 7:46 am